Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1001 to 1050 of 1515 results for patients and public

  1. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

  2. Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)

    NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms

  3. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

  4. Acute heart failure (QS103)

    This quality standard covers the care of adults (aged 18 and over) with suspected or confirmed acute heart failure. It describes high-quality care in priority areas for improvement.

  5. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

  6. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

  7. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]

    Awaiting development Reference number: GID-TA11222 Expected publication date: TBC

  8. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

  9. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

  10. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

  11. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

  12. NICE and virtual wards

    We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.

  13. NICE decision aid: process guide (PMG42)

    This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups

  14. Immunisation: shingles (IND219)

    This indicator covers the percentage of patients who reached 75 years old in the preceding 12 months, who have received a shingles vaccine between the ages of 70 and 75 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM201

  15. Scleral expansion surgery for presbyopia (HTG43)

    Evidence-based recommendations on scleral expansion surgery for presbyopia. This involves making small incisions in the eye and inserting bands to stretch part of the sclera.

  16. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development Reference number: GID-TA11018 Expected publication date: TBC

  17. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC

  18. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

  19. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  20. AccuVein AV400 for vein visualisation (MIB6)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation

  21. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

  22. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.

  23. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  24. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

  25. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

  26. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    In development Reference number: GID-TA11307 Expected publication date:  06 January 2027

  27. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

  28. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

  29. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]

    In development Reference number: GID-TA11437 Expected publication date: TBC

  30. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  31. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

  32. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  33. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  34. Collagen injection for vocal cord augmentation (HTG79)

    Evidence-based recommendations on collagen injection for vocal cord augmentation. This involves injecting collagen into the affected vocal cord(s).

  35. Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)

    This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

  36. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  37. Workplace health: long-term sickness absence and capability to work (NG146)

    This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.

  38. Indicator advisory committee (IAC)

    Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.

  39. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  40. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

  41. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

  42. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

  43. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTE10079 Expected publication date:  27 January 2027

  44. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  45. Interim methods guide for developing service guidance 2014 (PMG8)

    This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance

  46. Laparoscopic insertion of peritoneal dialysis catheter (HTG133)

    Evidence-based recommendations on laparoscopic insertion of peritoneal dialysis catheter. This involves inserting a tube through small cuts (keyhole surgery) in the abdomen to remove waste product from the blood.

  47. Automated percutaneous mechanical lumbar discectomy (HTG88)

    Evidence-based recommendations on automated percutaneous mechanical lumbar discectomy. This involves using an automated device to cut and remove the part of the disc that’s pressing on the nerve.

  48. Photodynamic therapy for bile duct cancer (HTG82)

    Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.

  49. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  50. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.